Latest 3SBio Inc. Stories
SHENYANG, China and VILLA GUARDIA, Italy, Jan.
-- DIG-KT is a novel bi-specific mAb targeting VEGFR2 and Tie-2 pathways for treating cancers SHENYANG, China and DAEJEON, South Korea, Jan. 14, 2015 /PRNewswire/ -- 3SBio Inc.
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
-- PEG-Irinotecan is a novel, long-acting polymer-drug conjugate which inhibits Topo-I associated with solid tumors SHENYANG, China, Sept.
Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug.
-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory
- A political dynamiter.